Skip to main content
Erschienen in: BMC Urology 1/2018

Open Access 01.12.2018 | Correction

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

verfasst von: Neil M Schultz, Neal D Shore, Simon Chowdhury, Laurence H Klotz, Raoul S Concepcion, David F Penson, Lawrence I Karsh, Hongbo Yang, Bruce A Brown, Arie Barlev, Scott C Flanders

Erschienen in: BMC Urology | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s12894-018-0387-7

Correction to Schultz et al. BMC Urology (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.
Incorrect:
The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.
Correct:
The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.CrossRef Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.CrossRef
Metadaten
Titel
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
verfasst von
Neil M Schultz
Neal D Shore
Simon Chowdhury
Laurence H Klotz
Raoul S Concepcion
David F Penson
Lawrence I Karsh
Hongbo Yang
Bruce A Brown
Arie Barlev
Scott C Flanders
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Urology / Ausgabe 1/2018
Elektronische ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-018-0397-5

Weitere Artikel der Ausgabe 1/2018

BMC Urology 1/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.